Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Am J Hematol. 2018 Nov 15;94(1):111–117. doi: 10.1002/ajh.25333

Table 1:

Patient Characteristics at Study Entry

Variable Category CT FLAM S-MEC Total
Total 35 36 19 90
Age Median (Q1,Q3) 55 (48,62) 62 (52,67) 55 (42,63) 57 (48,64)
Gender Male 21(60%) 22(61%) 11(58%) 54(60%)
Female 14(40%) 14(39%) 8(42%) 36(40%)
Race White 33(94%) 30(86%) 13(72%) 76(86%)
Black 1(3%) 4(11%) 2(11) 7(8%)
Asian 1(3%) 1(3%) 2(11%) 4(5%)
Multi-race 0(0.0) 0(0.0) 1(6%) 1(1%)
Unknown/Missing 0 1 1 2
Disease Status < 6 mos after 1st
CR
9(26%) 11(31%) 6(33%) 26(29%)
6–12 mos after 1st
CR
8(23%) 8(22%) 3(17%) 19(21%)
Refractory 18(51%) 17(47%) 9(50%) 44(49%)
Unknown/Missing 0 0 1 1
ECOG Performance 0 10(29%) 11(31%) 4(22%) 25(28%)
Status 1 19(54%) 21(58%) 12(67%) 52(58%)
2 6(17%) 4(11%) 2(11%) 12(13%)
Unknown/Missing 0 0 1 1
Leukemia FAB M1 3(9%) 6(17%) 3(17%) 12(13%)
Classification FAB M2 8(23%) 2(6%) 2(11%) 12(13%)
FAB M4 2(6%) 4(11%) 3(17%) 9(10%)
FAB M5 4(11%) 3(8%) 0 7(8%)
FAB M6 1(3%) 2(6%) 0 3(3%)
FAB M0 2(6%) 0 0 2(2%)
Acute myeloid
leukemia with
multilineage
dysplasia
0 3(8%) 2(11%) 5(6%)
Therapy-related
acute myeloid
leukemia, NOS
1(3%) 2(6%) 0 3(3%)
Acute myeloid
leukemia, NOS
14(40%) 14(39%) 8(44%) 36(40%)
Unknown/Missing 0 0 1 1
Marrow Blast (%) Median (Q1,Q3) 58.0 (21.0,80.0) 48.0 (21.0,66.5) 40.0 (29.0,79.0) 49.0 (22.0,78.5)
[Min, Max] [10.0,95.0] [6.0,97.0] [15.0,95.0] [6.0,97.0]
Unknown/Missing 1 1 2 4
WBC (× 103/mm3) Median (Q1,Q3) 5 (2,8) 2 (1,5) 3 (2,4) 3 (2,6)
[Min, Max] [0,119] [0,134] [0,73] [0,134]
Granulocytes Median (Q1,Q3) 1371 (312,2642) 684 (210,2140) 728 (265,1375) 850 (210,2370)
(AGC/ANC) [Min, Max] [0,35070] [0,17750] [0,4900] [0,35070]
Unknown/Missing 3 2 0 5
Platelet (× 103/mm3) Median (Q1,Q3) 42 (22,79) 32 (18,65) 65 (26,175) 42 (21,85)
[Min, Max] [11,206] [6,252] [8,310] [6,310]
Hemoglobin (g/dl) Median (Q1,Q3) 10 (8,11) 10 (9,10) 10 (9,11) 10 (9,11)
[Min, Max] [7,15] [8,15] [8,13] [7,15]